A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction
Study sponsor: Ionis Pharmaceuticals, Inc. · IONS
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-10-19Actual
Enrollment · participants72Actual
Source updated2023-09-11Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.